US EditionPublished • loading... • Updated
Electra Pursues Rare Inflammatory Disease and More with $183M Financing
Electra Therapeutics has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) that could be the first drug to be authorized for the rare, potentially fatal severe, systemic inflammatory syndrome. The financing will also support the development of a potential second indication in blood cance…
1 Articles
1 Articles
Electra Pursues Rare Inflammatory Disease and More with $183M Financing
Electra Therapeutics has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) that could be the first drug to be authorized for the rare, potentially fatal severe, systemic inflammatory syndrome. The financing will also support the development of a potential second indication in blood cance…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
